Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules.

The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas.

In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.

Key Stats

• Today's Range: $4.55 to $4.80
• 50-Day Range: $3.64 to $5.93
• 52-Week Range: $3.53 to $5.76
• Volume: 3.10 million shs
• Average Volume: 76,658 shs
• Market Capitalization: $7.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TTNP Stock Analysis - Frequently Asked Questions

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its quarterly earnings data on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals shares reverse split on Tuesday, January 9th 2024.The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TTNP
• CIK: 910267
• Web: www.titanpharm.com
• Phone: (650) 244-4990
• Fax: 650-244-4956
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($2.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.60%
• Return on Assets: -95.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.60
• Quick Ratio: 11.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 2.22

Miscellaneous

• Outstanding Shares: 1,330,000
• Free Float: 1,320,000
• Market Cap: $7.88 million
• Optionable: Optionable
• Beta: 1.37